se of monomeric and oligomeric flavanols in the dietary management of patients with type 2 diabetes and microalbuminuria

Erasmus Medical Center, Department of Internal Medicine0 个研究点目标入组 96 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•Age 40-85 years
•Microalbuminuria in the previous 6 months (as microalbuminuria can change during time, results shouldn’t be older than 6 months), defined as:
•- 30-300 mg albumin in a 24-hour urine sample
•- or 3.5-35 mg albumin/mmol creatinine in females and 2.5-25 mg albumin/mmol creatinine in males in a urine portion.
•This definition is derived from the Dutch national guidelines.

•Other types of diabetes mellitus as derived from the medical records
•Prior (less than 4 weeks before participating) or current use of any specific dietary supplementary products providing daily amounts of MOF of 25 mg/day or higher
•Anticoagulation medication
•Major health conditions: organ transplantation, untreated cancer, current chemotherapy or radiotherapy, acute or chronic organ failure
•Microalbuminuria due to other conditions than T2D
•Pregnancy or lactation during the trial

发起方

Erasmus Medical Center, Department of Internal Medicine